Investing
First Look Analysts Research Calls for Thursday, January 5
Published:
Last Updated:
This report was sent to Briefing.com subscribers earlier today.
Upgrades:
> Cullen/Frost (CFR) upgraded to Buy from Neutral at BofA Securities; tgt $155
> FibroGen (FGEN) upgraded to Buy from Neutral at BofA Securities; tgt raised to $27
> Interpublic (IPG) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $36
> Olin (OLN) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $65
> Group of America (RGA) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $167
Downgrades:
> Pearson Plc (PSO) downgraded to Underperform from Neutral at BofA Securities
> PNC (PNC) downgraded to Underperform from Neutral at BofA Securities; tgt raised to $160
> Prudential Plc (PUK) downgraded to Underperform from Neutral at Exane BNP Paribas
Others:
> Adaptimmune Therapeutics (ADAP) initiated with a Buy at EF Hutton; tgt $15
> Adaptive Biotechnologies (ADPT) initiated with a Sector Outperform at Scotiabank; tgt $15
> Allogene (ALLO) initiated with a Buy at EF Hutton; tgt $15
> Amylyx Pharmaceuticals (AMLX) initiated with a Buy at BofA Securities; tgt $50
> Atara Biotherapeutics (ATRA) initiated with a Buy at EF Hutton; tgt $25
> Bicycle Therapeutics (BCYC) initiated with a Buy at EF Hutton; tgt $55
> BioAtla (BCAB) initiated with a Buy at EF Hutton; tgt $25
> Bionano Genomics (BNGO) initiated with a Sector Outperform at Scotiabank; tgt $4
> Century Therapeutics (IPSC) initiated with a Buy at EF Hutton; tgt $18
> CRISPR Therapeutics (CRSP) initiated with a Buy at EF Hutton; tgt $75
> Fate Therapeutics (FATE) initiated with a Buy at EF Hutton; tgt $16
> G1 Therapeutics (GTHX) initiated with a Buy at EF Hutton; tgt $35
> Merus (MRUS) initiated with a Buy at EF Hutton; tgt $35
> Pacific Biosciences (PACB) initiated with a Sector Outperform at Scotiabank; tgt $12
> Rain Oncology (RAIN) initiated with a Buy at EF Hutton; tgt $16
> Replimune (REPL) initiated with a Buy at EF Hutton; tgt $60
> Twist Bioscience (TWST) initiated with a Sector Outperform at Scotiabank; tgt $33
> Veracyte (VCYT) initiated with a Sector Outperform at Scotiabank; tgt $33
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
